<?xml version='1.0' encoding='utf-8'?>
<document id="29739809"><sentence text="Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein."><entity charOffset="79-88" id="DDI-PubMed.29739809.s1.e0" text="Bosutinib" /></sentence><sentence text="Bosutinib is an orally available Src/Abl tyrosine kinase inhibitor indicated for the treatment of patients with Ph+ chronic myelogenous leukemia at a clinically recommended dose of 500 mg once daily"><entity charOffset="0-9" id="DDI-PubMed.29739809.s2.e0" text="Bosutinib" /><entity charOffset="41-49" id="DDI-PubMed.29739809.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29739809.s2.e0" e2="DDI-PubMed.29739809.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29739809.s2.e0" e2="DDI-PubMed.29739809.s2.e1" /></sentence><sentence text=" Clinical results indicated that increases in bosutinib oral exposures were supraproportional at the lower doses (50-200 mg) and approximately dose-proportional at the higher doses (200-600 mg)"><entity charOffset="46-55" id="DDI-PubMed.29739809.s3.e0" text="bosutinib" /></sentence><sentence text=" Bosutinib is a substrate of CYP3A4 and P-glycoprotein and exhibits pH-dependent solubility with moderate intestinal permeability"><entity charOffset="1-10" id="DDI-PubMed.29739809.s4.e0" text="Bosutinib" /></sentence><sentence text=" These findings led us to investigate the factors influencing the underlying pharmacokinetic mechanisms of bosutinib with physiologically based pharmacokinetic (PBPK) models"><entity charOffset="107-116" id="DDI-PubMed.29739809.s5.e0" text="bosutinib" /></sentence><sentence text=" Our primary objectives were to: 1) refine the previously developed bosutinib PBPK model on the basis of the latest oral bioavailability data and 2) verify the refined PBPK model with P-glycoprotein kinetics on the basis of the bosutinib drug-drug interaction (DDI) results with ketoconazole and rifampin"><entity charOffset="228-237" id="DDI-PubMed.29739809.s6.e0" text="bosutinib" /><entity charOffset="279-291" id="DDI-PubMed.29739809.s6.e1" text="ketoconazole" /><entity charOffset="296-304" id="DDI-PubMed.29739809.s6.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.29739809.s6.e0" e2="DDI-PubMed.29739809.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29739809.s6.e0" e2="DDI-PubMed.29739809.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29739809.s6.e0" e2="DDI-PubMed.29739809.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29739809.s6.e1" e2="DDI-PubMed.29739809.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29739809.s6.e1" e2="DDI-PubMed.29739809.s6.e2" /></sentence><sentence text=" Additionally, the verified PBPK model was applied to predict bosutinib DDIs with dual CYP3A/P-glycoprotein inhibitors" /><sentence text=" The results indicated that 1) the refined PBPK model adequately described the observed plasma concentration-time profiles of bosutinib and 2) the verified PBPK model reasonably predicted the effects of ketoconazole and rifampin on bosutinib exposures by accounting for intestinal P-glycoprotein inhibition/induction"><entity charOffset="126-135" id="DDI-PubMed.29739809.s8.e0" text="bosutinib" /><entity charOffset="203-215" id="DDI-PubMed.29739809.s8.e1" text="ketoconazole" /><entity charOffset="220-228" id="DDI-PubMed.29739809.s8.e2" text="rifampin" /><entity charOffset="232-241" id="DDI-PubMed.29739809.s8.e3" text="bosutinib" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e0" e2="DDI-PubMed.29739809.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e0" e2="DDI-PubMed.29739809.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e0" e2="DDI-PubMed.29739809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e0" e2="DDI-PubMed.29739809.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e1" e2="DDI-PubMed.29739809.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e1" e2="DDI-PubMed.29739809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e1" e2="DDI-PubMed.29739809.s8.e3" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e2" e2="DDI-PubMed.29739809.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29739809.s8.e2" e2="DDI-PubMed.29739809.s8.e3" /></sentence><sentence text=" These results suggested that bosutinib DDI mechanism could involve not only CYP3A4-mediated metabolism but also P-glycoprotein-mediated efflux on absorption" /><sentence text=" In summary, P-glycoprotein kinetics could constitute an element in the PBPK models critical to understanding the pharmacokinetic mechanism of dual CYP3A/P-glycoprotein substrates, such as bosutinib, that exhibit nonlinear pharmacokinetics owing largely to a saturation of intestinal P-glycoprotein-mediated efflux"><entity charOffset="189-198" id="DDI-PubMed.29739809.s10.e0" text="bosutinib" /></sentence><sentence text="" /></document>